Drug intelligence / Profile preview

OVUNOL

Development stage: Unknown
Lead developer: Effik
Modality: Small Molecules
Administration: Oral

Overview

OVUNOL is a multi-ingredient dietary supplement developed by the French pharmaceutical company Effik, designed to support the nutritional requirements of women seeking to conceive and to promote normal fertility. The formulation includes myo-inositol as its primary component, alongside zinc, selenium, iodine, vitamin D, and an active form of folate known as Quatrefolic (5-methyltetrahydrofolate). Zinc is included for its role in normal fertility and reproduction, while selenium serves as an antioxidant to protect cells from oxidative stress. OVUNOL is administered as a daily orodispersible powder dissolved in water and is positioned as a fertility-enhancing nutraceutical rather than a prescription pharmaceutical.

Brand names: OVUNOLOVUNOL Fertilité

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on OVUNOL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OVUNOL.

Explore the full profile